Hydrogen sulfide (H2S)/cystathionine γ-lyase (CSE) pathway contributes to the proliferation of hepatoma cells

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 763-764, Issue , 2014, Pages 10-18

  Pan, Yan ^a   Ye, Shuang ^a   Yuan, Dexiao ^a   Zhang, Jianghong ^a   Bai, Yang ^a   Shao, Chunlin ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Apoptosis; EGFR; ERK1 2; H 2 S CSE; Hepatoma cells; Proliferation

Indexed keywords

CASPASE 3; CYSTATHIONINE GAMMA LYASE; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; HYDROGEN SULFIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; BAX PROTEIN, HUMAN; BCL2 PROTEIN, HUMAN; CASP3 PROTEIN, HUMAN; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; MAPK1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; TP53 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DNA DAMAGE; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HEPATOMA CELL; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; CELL SURVIVAL; HEPG2 CELL LINE; LIVER CELL CARCINOMA; LIVER MITOCHONDRION; LIVER TUMOR; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA, HEPATOCELLULAR; CASPASE 3; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYSTATHIONINE GAMMA-LYASE; DNA DAMAGE; HEP G2 CELLS; HUMANS; HYDROGEN SULFIDE; LIVER NEOPLASMS; MAP KINASE KINASE 4; MAP KINASE SIGNALING SYSTEM; MITOCHONDRIA, LIVER; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84897372793     PISSN: 00275107     EISSN: 09218262     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2014.03.002     Document Type: Article

References (40)

1. Farazi P.A., DePinho R.A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer 2006, 6:674-687.
2. Kimura H. Hydrogen sulfide as a neuromodulator. Mol. Neurobiol. 2002, 26:13-19.
3. Hosoki R., Matsuki N., Kimura H. The possible role of hydrogen sulfide as an endogenous smooth muscle relaxant in synergy with nitric oxide. Biochem. Biophys. Res. Commun. 1997, 237:527-531.
4. 2S production in murine tissues. Antioxid. Redox Signal. 2011, 15:363-372.
5. (2)S/CSE pathway in Chang liver cells. Mutat. Res. 2012, 738-739:12-18.
6. Predmore B.L., Lefer D.J., Gojon G. Hydrogen sulfide in biochemistry and medicine. Antioxid. Redox Signal. 2012, 17:119-140.
7. 2S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine gamma-lyase. Science 2008, 322:587-590.
8. Yusuf M., Kwong Huat B.T., Hsu A., Whiteman M., Bhatia M., Moore P.K. Streptozotocin-induced diabetes in the rat is associated with enhanced tissue hydrogen sulfide biosynthesis. Biochem. Biophys. Res. Commun. 2005, 333:1146-1152.
9. Abe K., Kimura H. The possible role of hydrogen sulfide as an endogenous neuromodulator. J. Neurosci. 1996, 16:1066-1071.
10. Baskar R., Sparatore A., Del Soldato P., Moore P.K. Effect of S-diclofenac, a novel hydrogen sulfide releasing derivative inhibit rat vascular smooth muscle cell proliferation. Eur. J. Pharmacol. 2008, 594:1-8.
11. Papapetropoulos A., Pyriochou A., Altaany Z., Yang G., Marazioti A., Zhou Z., Jeschke M.G., Branski L.K., Herndon D.N., Wang R., Szabo C. Hydrogen sulfide is an endogenous stimulator of angiogenesis. Proc. Nat. Acad. Sci. U.S.A. 2009, 106:21972-21977.
12. 2S treatment in human lung fibroblasts. J. Cell. Mol. Med. 2008, 12:2297-2300.
13. Coletta C., Papapetropoulos A., Erdelyi K., Olah G., Modis K., Panopoulos P., Asimakopoulou A., Gero D., Sharina I., Martin E., Szabo C. Hydrogen sulfide and nitric oxide are mutually dependent in the regulation of angiogenesis and endothelium-dependent vasorelaxation. Proc. Nat. Acad. Sci. U.S.A. 2012, 109:9161-9166.
14. Cai W.J., Wang M.J., Ju L.H., Wang C., Zhu Y.C. Hydrogen sulfide induces human colon cancer cell proliferation: role of Akt, ERK and p21. Cell Biol. Int. 2010, 34:565-572.
15. Rose P., Moore P.K., Ming S.H., Nam O.C., Armstrong J.S., Whiteman M. Hydrogen sulfide protects colon cancer cells from chemopreventative agent beta-phenylethyl isothiocyanate induced apoptosis. World J. Gastroenterol. 2005, 11:3990-3997.
16. Lee Z.W., Zhou J., Chen C.S., Zhao Y., Tan C.H., Li L., Moore P.K., Deng L.W. The slow-releasing hydrogen sulfide donor, GYY4137, exhibits novel anti-cancer effects in vitro and in vivo. PLoS One 2011, 6:e21077.
17. (2)S/cystathionine gamma-lyase modulation. Mutat. Res. 2011, 707:67-73.
18. Iarmarcovai G., Bonassi S., Botta A., Baan R.A., Orsiere T. Genetic polymorphisms and micronucleus formation: a review of the literature. Mutat. Res. 2008, 658:215-233.
19. Yin W.L., He J.Q., Hu B., Jiang Z.S., Tang X.Q. Hydrogen sulfide inhibits MPP(+)-induced apoptosis in PC12 cells. Life Sci. 2009, 85:269-275.
20. Vitvitsky V., Thomas M., Ghorpade A., Gendelman H.E., Banerjee R. A functional transsulfuration pathway in the brain links to glutathione homeostasis. J. Biol. Chem. 2006, 281:35785-35793.
21. Danial N.N., Korsmeyer S.J. Cell death: critical control points. Cell 2004, 116:205-219.
22. Fulda S., Debatin K.M. Sensitization for anticancer drug-induced apoptosis by the chemopreventive agent resveratrol. Oncogene 2004, 23:6702-6711.
23. Miyashita T., Reed J.C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995, 80:293-299.
24. Amato S.F., Swart J.M., Berg M., Wanebo H.J., Mehta S.R., Chiles T.C. Transient stimulation of the c-Jun-NH2-terminal kinase/activator protein 1 pathway and inhibition of extracellular signal-regulated kinase are early effects in paclitaxel-mediated apoptosis in human B lymphoblasts. Cancer Res. 1998, 58:241-247.
25. Chen F. JNK-induced apoptosis, compensatory growth, and cancer stem cells. Cancer Res. 2012, 72:379-386.
26. Pelicano H., Carney D., Huang P. ROS stress in cancer cells and therapeutic implications. Drug Resist. Updat. 2004, 7:97-110.
27. Storz P. Reactive oxygen species in tumor progression. Front Biosci. 2005, 10:1881-1896.
28. Circu M.L., Aw T.Y. Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic. Biol. Med. 2010, 48:749-762.
29. Raj L., Ide T., Gurkar A.U., Foley M., Schenone M., Li X., Tolliday N.J., Golub T.R., Carr S.A., Shamji A.F., Stern A.M., Mandinova A., Schreiber S.L., Lee S.W. Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature 2012, 475:231-234.
30. Zhou Y., Hileman E.O., Plunkett W., Keating M.J., Huang P. Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents. Blood 2003, 101:4098-4104.
31. Manna A., Saha P., Sarkar A., Mukhopadhyay D., Bauri A.K., Kumar D., Das P., Chattopadhyay S., Chatterjee M. Malabaricone-A induces a redox imbalance that mediates apoptosis in U937 cell line. PLoS One 2012, 7:e36938.
32. Ahamed M., Akhtar M.J., Raja M., Ahmad I., Siddiqui M.K., AlSalhi M.S., Alrokayan S.A. ZnO nanorod-induced apoptosis in human alveolar adenocarcinoma cells via p53, survivin and bax/bcl-2 pathways: role of oxidative stress. Nanomedicine 2011, 7:904-913.
33. Diwakar L., Ravindranath V. Inhibition of cystathionine-gamma-lyase leads to loss of glutathione and aggravation of mitochondrial dysfunction mediated by excitatory amino acid in the CNS. Neurochem. Int. 2007, 50:418-426.
34. Suzuki K., Olah G., Modis K., Coletta C., Kulp G., Gero D., Szoleczky P., Chang T., Zhou Z., Wu L., Wang R., Papapetropoulos A., Szabo C. Hydrogen sulfide replacement therapy protects the vascular endothelium in hyperglycemia by preserving mitochondrial function. Proc. Nat. Acad. Sci. U.S.A. 2011, 108:13829-13834.
35. Berasain C., Castillo J., Prieto J., Avila M.A. New molecular targets for hepatocellular carcinoma: the ErbB1 signaling system. Liver Int. 2007, 27:174-185.
36. Roberts P.J., Der C.J. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007, 26:3291-3310.
37. Wells A. EGF receptor. Int. J. Biochem. Cell Biol. 1999, 31:637-643.
38. Plotnikov A., Chuderland D., Karamansha Y., Livnah O., Seger R. Nuclear extracellular signal-regulated kinase 1 and 2 translocation is mediated by casein kinase 2 and accelerated by autophosphorylation. Mol. Cell. Biol. 2011, 31:3515-3530.
39. Caja L., Sancho P., Bertran E., Iglesias-Serret D., Gil J., Fabregat I. Overactivation of the MEK/ERK pathway in liver tumor cells confers resistance to TGF-{beta}-induced cell death through impairing up-regulation of the NADPH oxidase NOX4. Cancer Res. 2009, 69:7595-7602.
40. Gan Y., Shi C., Inge L., Hibner M., Balducci J., Huang Y. Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells. Oncogene 2010, 29:4947-4958.